Sign In
Buy APDN
$5.62
+0 (+0%)
At Close: Jan 05, 2026
Applied DNA Submits Validation Package to New York State Department of Health for H5 Bird Flu/Pan-Influenza A Laboratory-Developed Test
09:00am, Wednesday, 26'th Mar 2025
STONY BROOK, NY / ACCESS Newswire / March 26, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA or the "Company"), a leader in PCR-based DNA technologies, today announced that Applied DNA C
Applied DNA Announces 1-For-50 Reverse Stock Split Effective March 14, 2025
08:00am, Wednesday, 12'th Mar 2025
STONY BROOK, NY / ACCESS Newswire / March 12, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA or the "Company"), a leader in PCR-based DNA technologies, today announced that it will effec
Applied DNA Sciences, Inc. (APDN) Q1 2025 Earnings Call Transcript
02:10pm, Friday, 14'th Feb 2025
Applied DNA Sciences, Inc. (NASDAQ:APDN ) Q1 2025 Earnings Conference Call February 13, 2025 4:30 PM ET Company Participants Sanjay Hurry - Executive Director, IR & Corporate Communications Beth Jantz
Applied DNA Sciences (APDN) Reports Q1 Loss, Tops Revenue Estimates
06:21pm, Thursday, 13'th Feb 2025
Applied DNA Sciences (APDN) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $1.80 per share a year ago.
Applied DNA Reports First Quarter Fiscal 2025 Financial Results and Highlights Operational Progress
04:03pm, Thursday, 13'th Feb 2025
- Announces Exit of DNA Tagging and Security Products and Services Business Segment - - Workforce Reduction of 20% of Headcount Implemented in January - - GMP Site 1 Facility Complete and Certified fo
Applied DNA to Report First Quarter Fiscal 2025 Financial Results After Market Close on Thursday, February 13, 2025
12:00pm, Wednesday, 12'th Feb 2025
Investor Call and Webcast Scheduled for 4:30 P.M ET STONY BROOK, NY / ACCESS Newswire / February 12, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polym
Applied DNA Reminds Shareholders to Vote Ahead of Special Meeting on February 14
08:30am, Tuesday, 11'th Feb 2025
STONY BROOK, NY / ACCESS Newswire / February 11, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today issued a reminder to it
Applied DNA Completes Buildout of GMP Facility for LineaDNA IVT Templates
09:00am, Friday, 10'th Jan 2025
- Signals Start of New Commercialization Phase for LineaRx Subsidiary - - Company Negotiating GMP Supply Agreement - - Company Reaffirms Strategic Restructuring Timeline - STONY BROOK, NY / ACCESSWIRE
STONY BROOK, NY / ACCESSWIRE / January 8, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announ
Applied DNA Customer ÚHKT Initiates Phase I Clinical Trial for Rapidly Manufacturable CAR T-Cell Therapy Produced from Linea DNA
09:00am, Wednesday, 18'th Dec 2024
- Regulatory Approval Showcases Clinical Advancement of Linea DNA™ as a Rapid and Effective Means of Producing CAR-T cell Therapies - STONY BROOK, NY / ACCESSWIRE / December 18, 2024 / Applied DNA S
Applied DNA Sciences (APDN) Reports Q4 Loss, Tops Revenue Estimates
06:15pm, Tuesday, 17'th Dec 2024
Applied DNA Sciences (APDN) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $5.20 per share a year ago.
- Pursuing Divestiture of CertainT® Platform, Implements Changes to Corporate Leadership - - Build-out of GMP Manufacturing Facility to be Completed by January 9, 2025 - - Webcast and Conference Call
STONY BROOK, NY / ACCESSWIRE / December 16, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today anno
Applied DNA Announces Pricing of $6.5 Million Registered Direct Offering and Concurrent Private Placement
07:15am, Wednesday, 30'th Oct 2024
STONY BROOK, NY / ACCESSWIRE / October 30, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced the pricing of a re
Applied DNA to Participate in the 2024 Maxim Healthcare Virtual Summit on Wednesday, October 16
10:30am, Tuesday, 15'th Oct 2024
STONY BROOK, NY / ACCESSWIRE / October 15, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA"), a leader in PCR-based DNA technologies, today announced that Dr. James A. Hayward, president
